Spago Nanomedical Management
Management criteria checks 2/4
Spago Nanomedical's CEO is Mats Hansen, appointed in Jan 2015, has a tenure of 9.42 years. total yearly compensation is SEK2.40M, comprised of 72.3% salary and 27.7% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth SEK117.88K. The average tenure of the management team and the board of directors is 4.1 years and 1.1 years respectively.
Key information
Mats Hansen
Chief executive officer
kr2.4m
Total compensation
CEO salary percentage | 72.3% |
CEO tenure | 9.4yrs |
CEO ownership | 0.1% |
Management average tenure | 4.1yrs |
Board average tenure | 1.1yrs |
Recent management updates
Recent updates
Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation
Jun 04We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn
Sep 21We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow
May 26Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven
Mar 30We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely
Feb 03Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term
Dec 11CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -kr34m |
Dec 31 2023 | kr2m | kr2m | -kr42m |
Sep 30 2023 | n/a | n/a | -kr42m |
Jun 30 2023 | n/a | n/a | -kr43m |
Mar 31 2023 | n/a | n/a | -kr45m |
Dec 31 2022 | kr2m | kr2m | -kr39m |
Sep 30 2022 | n/a | n/a | -kr39m |
Jun 30 2022 | n/a | n/a | -kr41m |
Mar 31 2022 | n/a | n/a | -kr43m |
Dec 31 2021 | kr2m | kr1m | -kr39m |
Sep 30 2021 | n/a | n/a | -kr32m |
Jun 30 2021 | n/a | n/a | -kr27m |
Mar 31 2021 | n/a | n/a | -kr20m |
Dec 31 2020 | kr2m | kr1m | -kr19m |
Sep 30 2020 | n/a | n/a | -kr20m |
Jun 30 2020 | n/a | n/a | -kr21m |
Mar 31 2020 | n/a | n/a | -kr21m |
Dec 31 2019 | kr2m | kr1m | -kr20m |
Sep 30 2019 | n/a | n/a | -kr18m |
Jun 30 2019 | n/a | n/a | -kr15m |
Mar 31 2019 | n/a | n/a | -kr13m |
Dec 31 2018 | kr1m | kr1m | -kr11m |
Compensation vs Market: Mats's total compensation ($USD228.34K) is about average for companies of similar size in the Swedish market ($USD258.01K).
Compensation vs Earnings: Mats's compensation has increased whilst the company is unprofitable.
CEO
Mats Hansen (53 yo)
9.4yrs
Tenure
kr2,401,000
Compensation
Dr. Mats Hansen, MSc., PhD, serves as the Chief Executive Officer of Spago Nanomedical AB (publ) since 2015. Dr. Hansen has experience from different companies in the life science industry. He served at A...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 9.4yrs | kr2.40m | 0.11% SEK 117.9k | |
Chief Financial Officer | 5.4yrs | no data | 0.019% SEK 20.7k | |
Head of Research & Chief Scientific Officer | no data | no data | 0.048% SEK 51.3k | |
Chief Development Officer | 2.8yrs | no data | 0.017% SEK 18.4k | |
Head of CMC & Supply | no data | no data | no data |
4.1yrs
Average Tenure
54yo
Average Age
Experienced Management: SPAGO's management team is considered experienced (4.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Chairman of the Board | 1.1yrs | kr200.00k | 0.14% SEK 152.1k | |
Medical Advisor | 1.1yrs | kr32.00k | 0% SEK 0 | |
Independent Director | 1.1yrs | kr100.00k | 0.23% SEK 247.4k | |
Medical Advisor | 1.1yrs | kr32.00k | no data | |
Independent Director | 6.4yrs | kr132.00k | 0.057% SEK 61.2k | |
Medical Advisor | 2yrs | no data | no data | |
Independent Director | 4.8yrs | kr132.00k | 0.021% SEK 22.2k | |
Medical Advisor | 2yrs | no data | no data | |
Medical Advisor | 1.1yrs | no data | no data | |
Medical Advisor | less than a year | no data | no data |
1.1yrs
Average Tenure
65yo
Average Age
Experienced Board: SPAGO's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.